Figures & data
Figure 1 Druggable signaling pathways in endometrial cancer. Abbreviations: EGF, epidermal growth factor; IGF, insulin-like growth factor; TGFα, transforming growth factor α; FGF, fibroblast growth factor; HER, human epidermal growth factor receptor; EGFR, epidermal growth factor receptor; IGFR1, insulin-like growth factor receptor 1; FGFR2, fibroblast growth factor receptor 2; ATP, adenosine triphosphate; AMP, adenosine monophosphate; VEGF, vascular endothelial growth factor, PDGF, platelet-derived growth factor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; GRB2, growth factor receptor-bound protein 2; RAS, rat sarcoma gene; Raf, V-raf-1 murine leukemia viral oncogene homolog 1; MEK, mitogen activated protein kinase kinase; ERK, mitogen activate protein kinase; SRC, V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; IRS, insulin receptor substrate; PI3K, phosphatidylinositol 3 Kinase; PTEN, phosphatase and tensin homolog deleted on chromosome 10; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; AKT, v-akt murine thymoma viral oncogene homolog 1; PKA, protein kinase A; LKB1, liver kinase B1; AMPK, adenosine monophosphate kinase; mTORc, mammalian target of rapamycin Complex.
Figure 2 Comparison between tissue obtained from a primary hysterectomy specimen and tissue obtained from core needle biopsy at the time of recurrence. Recurrence tissues are much smaller, have less tumor cells, and commonly consist of tumor cells admixed with stroma. This latter feature may necessitate the use of laser capture microdissection prior to PCR-based molecular diagnostics testing.
Table 1 Molecular characterization of endometrial cancers by histologic subtype
Table 2 Molecules of importance in angiogenesis